TNF-blokkerende geneesmiddelen en infecties; adviezen voor de dagelijkse praktijk

J. W.G. Jacobs; M. C.W. Creemers; M. A. Van Agtmael; M. A.F.J. Van De Laar; T. Van Der Poll; P. P. Tak; J. W.J. Bijlsma

TNF-blokkerende geneesmiddelen en infecties; adviezen voor de dagelijkse praktijk

Translated title of the contribution: TNF-blocking drugs and infection; recommendations for daily practice

J. W.G. Jacobs, M. C.W. Creemers, M. A. Van Agtmael, M. A.F.J. Van De Laar, T. Van Der Poll, P. P. Tak, J. W.J. Bijlsma

Research output: Contribution to journal › Review article › Academic › peer-review

6 Citations (Scopus)

Abstract

- Anti-tumour necrosis factor (TNF) therapy is associated with an increased risk of infection. There are sparse data and no evidence-based guidelines on how to deal with this problem in daily practice. However, recommendations can be made based on theoretical considerations and by extrapolating from recommendations for other types of immunodeficiency. - Before starting anti-TNF therapy, screening for tuberculosis and other possible infections is indicated. During therapy, alertness is required to the increased risk of infection, infections with a more serious clinical course or unusual manifestations and opportunistic infections. - Flu vaccination during anti-TNF therapy is indicated. Travel vaccinations with live microbial inocula should not be given.

Translated title of the contribution	TNF-blocking drugs and infection; recommendations for daily practice
Original language	Dutch
Pages (from-to)	588-593
Number of pages	6
Journal	Nederlands Tijdschrift voor Geneeskunde
Volume	151
Issue number	10
Publication status	Published - 10 Mar 2007

Cite this

@article{9a471580c40c42c1835f36054223982d,

title = "TNF-blokkerende geneesmiddelen en infecties; adviezen voor de dagelijkse praktijk",

abstract = "- Anti-tumour necrosis factor (TNF) therapy is associated with an increased risk of infection. There are sparse data and no evidence-based guidelines on how to deal with this problem in daily practice. However, recommendations can be made based on theoretical considerations and by extrapolating from recommendations for other types of immunodeficiency. - Before starting anti-TNF therapy, screening for tuberculosis and other possible infections is indicated. During therapy, alertness is required to the increased risk of infection, infections with a more serious clinical course or unusual manifestations and opportunistic infections. - Flu vaccination during anti-TNF therapy is indicated. Travel vaccinations with live microbial inocula should not be given.",

author = "Jacobs, {J. W.G.} and Creemers, {M. C.W.} and {Van Agtmael}, {M. A.} and {Van De Laar}, {M. A.F.J.} and {Van Der Poll}, T. and Tak, {P. P.} and Bijlsma, {J. W.J.}",

year = "2007",

month = mar,

day = "10",

language = "Dutch",

volume = "151",

pages = "588--593",

journal = "Nederlands Tijdschrift voor Geneeskunde",

issn = "0028-2162",

publisher = "Vereniging Nederlands Tijdschrift voor Geneeskunde",

number = "10",

}

TY - JOUR

T1 - TNF-blokkerende geneesmiddelen en infecties; adviezen voor de dagelijkse praktijk

AU - Jacobs, J. W.G.

AU - Creemers, M. C.W.

AU - Van Agtmael, M. A.

AU - Van De Laar, M. A.F.J.

AU - Van Der Poll, T.

AU - Tak, P. P.

AU - Bijlsma, J. W.J.

PY - 2007/3/10

Y1 - 2007/3/10

N2 - - Anti-tumour necrosis factor (TNF) therapy is associated with an increased risk of infection. There are sparse data and no evidence-based guidelines on how to deal with this problem in daily practice. However, recommendations can be made based on theoretical considerations and by extrapolating from recommendations for other types of immunodeficiency. - Before starting anti-TNF therapy, screening for tuberculosis and other possible infections is indicated. During therapy, alertness is required to the increased risk of infection, infections with a more serious clinical course or unusual manifestations and opportunistic infections. - Flu vaccination during anti-TNF therapy is indicated. Travel vaccinations with live microbial inocula should not be given.

AB - - Anti-tumour necrosis factor (TNF) therapy is associated with an increased risk of infection. There are sparse data and no evidence-based guidelines on how to deal with this problem in daily practice. However, recommendations can be made based on theoretical considerations and by extrapolating from recommendations for other types of immunodeficiency. - Before starting anti-TNF therapy, screening for tuberculosis and other possible infections is indicated. During therapy, alertness is required to the increased risk of infection, infections with a more serious clinical course or unusual manifestations and opportunistic infections. - Flu vaccination during anti-TNF therapy is indicated. Travel vaccinations with live microbial inocula should not be given.

UR - http://www.scopus.com/inward/record.url?scp=33947708814&partnerID=8YFLogxK

M3 - Review article

C2 - 17402649

SN - 0028-2162

VL - 151

SP - 588

EP - 593

JO - Nederlands Tijdschrift voor Geneeskunde

JF - Nederlands Tijdschrift voor Geneeskunde

IS - 10

ER -

TNF-blokkerende geneesmiddelen en infecties; adviezen voor de dagelijkse praktijk

Abstract

Other files and links

Cite this